Our team at SQ Innovation has developed a novel drug formulation and a subcutaneous Infusor to deliver hospital-strength diuresis for at-home use. Thanks to its higher concentration of 30mg/mL, we can administer an 80mg therapeutic dose in a small volume of only 2.67mL.

We designed the Infusor specifically for our new furosemide formulation, aimed at patients with heart failure. In developing this product, we carefully considered the needs of patients, healthcare providers, payors and the environment. We named it Lasix® ONYU.

While subcutaneous drug delivery is not new—first developed in 1853—our goal is to make it more convenient, comfortable, affordable, and widely accessible.

Lasix® ONYU has received Tentative Approval from the U.S. Food and Drug Administration. This means the product meets all necessary safety, efficacy, labeling, and manufacturing requirements, though it has not yet been approved for sale